印度制药公司预计销售增长11%,超过诊断和医院的增长速度。 Indian pharmaceutical firms see projected 11% sales growth, outpacing diagnostics and hospitals.

根据Kotak的一份报告,预计印度制药公司销售量和EBITDA Q1FY26的年同比增长11%。 Pharmaceutical firms in India are projected to see an 11% year-on-year growth in sales and EBITDA for Q1FY26, according to a Kotak report. 预计医院部分的销售量将增长17%,而EBITDA的销售量将增长17%,而诊断量将增长14%。 The hospitals segment is expected to grow 17% in sales and EBITDA, while diagnostics are forecast to increase 14% in sales. 印度的制药市场价值达500亿美元,全球在非专利药品、疫苗和生物学方面的影响力很强。 India's pharmaceutical market is valued at $50 billion, with strong global presence in generics, vaccines, and biologics.